TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An analysis of prospectively logged menstrual cycles found that women reporting use of a combined GLP-1/GIP drug had a larger average reduction in cycle length than GLP-1-only users and non-users. The study showed an association, not proof that the drugs caused more regular cycles, and researchers say further research is needed.
An analysis of a prospective U.S. cohort found that women reporting use of a combined GLP-1/GIP receptor agonist had a larger reduction in menstrual cycle length than women taking a GLP-1 drug alone or neither type of medication. Presented at the American Society for Reproductive Medicine annual meeting, the findings suggest a possible link with menstrual regularity, but do not establish that the drugs caused the changes.
Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health, and colleagues analyzed 1,945 participants and 70,134 logged menstrual cycles in the Apple Women’s Health Study. Of the participants, 123 reported use of a combined GLP-1/GIP drug in the past year, 258 reported GLP-1 medication use, and 1,564 were never-users. The study compared changes in mean cycle length and variability across those groups.
Cycle length fell by an average of 2.5 days among combined-drug users, compared with 0.4 days among GLP-1 users and 0.8 days among never-users. Mean individual cycle variability was 6.93 days in the combined-drug group, 7.45 days among GLP-1 users and 7.46 days among never-users. These are group-level findings; the report does not establish that every participant experienced a more regular cycle.
In a subgroup of participants with polyendocrine metabolic ovarian syndrome, or PMOS, mean individual cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users. The source report describes PMOS as formerly known as polycystic ovary syndrome, or PCOS. Mahalingaiah said the subgroup result may point to a pathway involving ovulatory health, but stressed that further research is needed.
Why Cycle Changes Matter
Menstrual changes can matter beyond fertility. Rachel Weinerman, an ob/gyn and reproductive endocrinologist at Case Western Reserve University who was not involved in the research, told MedPage Today that irregular periods can also signal underlying health issues. The findings may therefore be relevant to patients and clinicians considering how metabolic conditions, weight changes and reproductive health intersect.
The result is also of interest because the study assessed prospectively logged cycles, rather than relying only on participants’ later recollections. Still, it is an observational association, not a clinical trial showing that a medication should be used to regulate periods. The study does not establish whether the observed differences came from the medication itself, weight loss, underlying conditions, or other factors.
Weinerman said weight loss can help some patients with PMOS achieve more regular cycles, and noted that people with PMOS may respond differently from others with similar characteristics. That interpretation offers one possible explanation for the subgroup result, not proof of a drug effect or a treatment recommendation.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Cycles
The Apple Women’s Health Study is a longitudinal digital cohort of about 147,000 U.S. women who log menstrual cycles. For this analysis, participants had to be younger than 50, have logged at least three cycles, and have cycle lengths between 10 and 90 days. Those who were pregnant, lactating or using hormones were excluded. Participants reported medication use and medical history and consented to share cycle logs; the analysis did not use sensor-based data.
Medication groups were based on reported use in the previous year. The groups differed in some characteristics: medication users were older on average and had higher parity, and a larger proportion had PMOS, infertility, type 2 diabetes or hypertension than never-users. These differences make it harder to attribute the cycle findings to medication alone.
Mahalingaiah said earlier retrospective studies had suggested a link between these medications and menstrual regularity, while this analysis examined logged cycles prospectively. The only GLP-1/GIP drug identified in the source report as FDA-approved is tirzepatide, sold as Zepbound. The study grouped medication use and did not report results by individual drug in this presentation.
“This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.”
— Shruthi Mahalingaiah, MD, MS, Harvard T.H. Chan School of Public Health
Limits of the Medication Link
The analysis cannot show that incretin drugs caused the observed cycle changes. Medication use was self-reported, and participants were not randomly assigned to treatment. Differences in age, medical history and reasons for taking medication—including weight loss and PMOS—could contribute to the results. The findings also do not identify which particular drug accounts for the group-level association.
The report does not provide enough detail to determine how cycle changes related to weight loss, dose, duration of treatment or changes in ovulation. Nor does it establish whether the differences were clinically meaningful for individual patients or persisted over time. Researchers said further study is necessary before drawing conclusions about a direct effect on ovulatory health.
Further Drug-Specific Results Ahead
Mahalingaiah said future manuscripts will break down the data by particular agents. Drug-specific results could help clarify whether the observed association is shared across medications or concentrated in one treatment, although additional research would still be needed to test cause and effect.
For now, the meeting analysis is evidence of a possible relationship, not a basis for prescribing incretin drugs to regulate menstrual cycles. The next steps are further analyses and research that can account for weight change, underlying conditions and treatment details.
Key Questions
Did the study prove incretin drugs make periods more regular?
No. It found an association between reported medication use and cycle measures in an observational cohort. It did not prove that the medications caused the changes.
Which group had the largest reduction in cycle length?
Participants reporting combined GLP-1/GIP drug use had an average reduction of 2.5 days, compared with 0.4 days among GLP-1 users and 0.8 days among never-users.
What did the analysis find for participants with PMOS?
In the PMOS subgroup, mean individual cycle variability was 5.80 days among combined-drug users, 7.34 days among GLP-1 users and 9.45 days among never-users. The subgroup finding needs further study.
Can these drugs be used to regulate menstrual cycles?
This analysis does not establish that incretin drugs should be used for that purpose. It was not a treatment trial, and the researchers said more research is needed.
What will researchers examine next?
Mahalingaiah said future manuscripts will report results by particular medications. Further research will be needed to determine whether any drug directly affects cycle regularity or ovulatory health.
Source: medpagetoday.com
